Full Committee Hearing

FDA, Merck and Vioxx: Putting Patient Safety First?

Date: Thursday, November 18, 2004 Time: 10:00 AM Location: 216 Hart Senate Office Building

There was no video broadcast for this event.

Member Statements

  1.  Chuck Grassley (R - IA)
  2. Senator Max Baucus (D - MT)


Panel I

  1. David Graham, M.D., M.P.H
    Associate Director for Science
    Office of Drug Safety, Center for Drug Evaluation and Research, Department of Health and Human Services, Food and Drug Administration
    Washington , DC

Panel II

  1. Gurkirpal Singh, M.D.
    Adjunct Clinical Professor of Medicine, Division of Gastroenterology and Hepatology
    Department of Medicine, Stanford University
    Stanford , CA
  2. Bruce Pstay, M.D., Ph.D.
    Professor, Medicine & Epidemiology
    University of Washington, Cardiovascular Health Research Unit
    Seattle , WA

Panel III

  1. Sandra Kweder, M.D.
    Acting Director, Office of New Drugs, Center for Drug Evaluation and Research
    Department of Health and Human Services, Food and Drug Administration
    Washington , DC

Panel IV

  1. Raymond Gilmartin
    Chairman, President & Chief Executive Officer
    Merck & Co.
    Whitehouse Station , NJ

Related Files

 How do I submit a statement for the record?

Any individual or organization wanting to present their views for inclusion in the hearing record should submit in a Word document, a single-spaced statement, not exceeding 10 pages in length. No other file type will be accepted for inclusion. Title and date of the hearing, and the full name and address of the individual or organization must appear on the first page of the statement. Statements must be received no later than two weeks following the conclusion of the hearing.

Statements can be emailed to:


Statements should be mailed (not faxed) to:

Senate Committee on Finance
Attn. Editorial and Document Section
Rm. SD-219
Dirksen Senate Office Bldg.
Washington, DC 20510-6200